Loading stock data…
WVE
$6.92-0.06 (-0.93%)
Market OpenUpdated 11:39 AM EDT
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Wave Life Sciences Ltd. in the Healthcare sector is trading at $7.09. Wall Street consensus targets $22.56 (16 analysts), implying a +218.4% move over the next 12 months. The stock is currently near its 52-week low of $5.02, remaining 30.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +218.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$6.92
Potential Downside
0%
Whystock Fair Value$6.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$22.56+225.8%
Range$12.00 – $43.00
Fundamentals
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multipl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.43%
Volume
Today's trading volume
1.12M
Recent News
Growth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%
Celebrations may be in order for Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders, with the analysts delivering a...
A Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price Decline
Wave Life Sciences (WVE) has drawn investor attention after recent share price swings, including a loss of around 54% year to date and a decline of about 43% over the past 3 months. See our latest analysis for Wave Life Sciences. Despite the steep year to date share price decline and a weak 90 day share price return, the recent 30 day share price gain and positive 3 year total shareholder return suggest shifting momentum around growth prospects and perceived risk. If you are comparing Wave...
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its Buy rating on March 26. The firm pointed out that Wave Life Sciences published more data from Arrowhead’s ARO-INHBE program, demonstrating that, despite the higher […]
Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary
Moby summary of Wave Life Sciences Ltd.'s Q1 2026 earnings call
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
WAVE Life Sciences Ltd (WVE) reports a significant revenue increase and advances in RNA programs, despite facing competitive and regulatory challenges.